Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2008

View Archived Issues

Daiichi Sankyo updates recent activity

AVI initiates next-generation drug eluting stent trial with Global Therapeutics

Novexel commences phase II for NXL-104/ceftazidime combination in UTIs

Quigley completes phase IIb study of QR-333 in diabetic peripheral neuropathy

Vical completes enrollment in phase II CMV vaccine trial

Phase IIa results with INCB-018424 in rheumatoid arthritis lead to phase IIb trials

Phase I data reported for autoimmune disorders candidate LX-2931

RAPID data show radiographic activity in nonresponders, sustained benefits in extension study

HIV protease inhibitor saquinavir kills ovarian cancer cells

ACH-702: new data on preclinical antibacterial activity, pharmacokinetics

Pfizer reports on sulopenem prodrug antibiotics

Seroquel approved in Europe for new indications in bipolar disorder

Sevikar approved in Germany for hypertension

Sanofi-aventis reports new post hoc results from ATHENA trial of Multaq in AF/AFL

Boehringer announces results from the PETRO-Ex study of Pradaxa for stroke in AF

Yissum and BioLineRx enter license agreement for antihormone BL-5040 in IBD

Swissmedic approves ceftobiprole for complicated skin and soft tissue infections

Nymox reports positive results in 59-week study of NX-1207 for BPS

Novel antiobesity agents disclosed in recent patents

Recent Novartis patent discloses novel antiinflammatory agents

New diagnostic agents imparted by Merck Eprova

Antyra and Novo Nordisk sign licensing agreement for IGF antagonists

Ensemble and Roche extend collaboration for diagnostic technology in cancer therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...